Outpatient therapy with @entity2600 and low-dose XXXX for metastatic @entity14 resistant to @entity1487 .

@entity1 @entity4181 @entity2600 @entity390 @entity5 @entity294 @entity900 @entity14 @entity1487 @entity1210
Chemotherapy with @entity2600 and low-dose @entity900 was tested for the treatment of metastatic @entity14 showing resistance to @entity1487 . Eleven consecutive @entity1 with advanced metastatic @entity14 (performance status: 0 to 2), who had shown @entity5 progression on chemotherapy with @entity1487 / @entity4181 , were treated with @entity2600 (60 mg/m2) plus @entity900 (6 mg/m2) by 90-min intravenous infusion. Treatment was repeated weekly for 3 weeks during admission and then fortnightly on an outpatient basis. Objective responses were observed in four @entity1 (36%; 95% confidence interval: 11%-69%). The median duration of response was 5.5 months and six @entity1 are still alive. The time to disease progression was longer in the no change group (7.0+/-3.6 months: mean +/- SD) than in the responder group (5.5+/-1.9 months), and there was no difference of median survival between the two groups (10.0 versus 10.3 months). The overall median survival was 8.2 months (range: 4 to 12+ months). This treatment was well tolerated. Six @entity1 experienced grade 1 or 2 @entity1210 , while grade I @entity294 and @entity390 occurred in three and five @entity1 , respectively. Based on the good response, excellent quality of life, and convenience, the present regimen seems to be reasonable second-line outpatient chemotherapy for @entity1 with metastatic @entity14 showing resistance to @entity1487 .
